Enrollment will begin in January 2026Participants will be treated with buntanetap for 36 monthsThe study aims to enroll 500 ...

Ophidion, Inc., a biotechnology company pioneering non-invasive delivery of gene-silencing and large-molecule therapeutics to the brain, and Neuronasal, Inc., a clinical-stage company advancing ...

Symptoms of Parkinson’s disease, such as tremors and stiffness, can make daily tasks difficult. A new drug has shown promise in alleviating symptoms. Tavapadon, a drug being tested to treat early ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

(Reuters) -AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday. Patients showed a statistically significant ...

A test that can detect Parkinson's disease in the early stages of the illness has moved a step closer. Scientists have developed a way of detecting a molecule linked to the condition in samples of ...

AC Immune (NASDAQ:ACIU) surged 25% on Thursday after announcing promising interim Phase 2 findings for its experimental ...

Annovis Bio Inc ($ANVS) announced an update on their ongoing clinical study. Study Overview Annovis Bio Inc. is launching a long-term safety study ...

Exercise in general can help patients manage symptoms, but without head-to-head trials, the ‘best’ exercise is the one the patient can do well and will stick with, experts say.

We've already seen a pen that helps people with Parkinson's disease to write clearly, but this one is a little different. By assessing its user's hand movements as they write, it can provide an early ...